

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Binding Protein

Field of the Invention

The present invention relates to proteins capable of binding
5 the E2 envelope protein of hepatitis C virus (HCV) and to
processes for production and purification.

The invention also relates to the use of the proteins in
therapy and diagnosis and to pharmaceutical compositions and
10 diagnostic kits for such uses. The invention also relates
to a process for screening putative molecules for
competition with HCV for receptor binding. The invention
also relates to an animal model for HCV infection.

15 Brief Description of the Prior Art

HCV (previously known as Non-A Non-B hepatitis - NANBV) is a
positive sense RNA virus of about 10000 nucleotides with a
single open reading frame encoding a polyprotein of about
20 3000 amino acids. Although the structure of the virus has
been elucidated by recombinant DNA techniques (1, 2), the
virus itself has not been isolated and the functions of the
various viral proteins produced by proteolysis of the
polyprotein have only been inferred by analogy with other
25 similar viruses of similar genomic organisation (3).

The viral proteins are all available in recombinant form,
expressed in a variety of cells and cell types, including
yeast, bacteria, insect and mammalian cells (4,5).

30

Two proteins, named E1 and E2 (corresponding to amino acids
192-383 and 384-750 respectively) have been suggested to be
external proteins of the viral envelope which are
responsible for the binding of virus to target cells (3).

35

HCV research is hindered very considerably by the limited
host range of the virus. The only reliable animal model for

HCV infection is the chimpanzee and it is not possible to propagate HCV in tissue culture.

In our copending International patent application
5 PCT/IB95/00692, we describe a method employing flow
cytometry to identify cells carrying the HCV receptor. We
have shown that, by labelling cells with recombinant E2
envelope protein, it is possible to sort cells using flow
cytometry, isolating those cells capable of specific binding
10 to the E2 and therefore potentially carrying the HCV
receptor. Employing this technique, we have identified a
protein capable of binding to the E2 envelope protein of HCV
which we believe to be the receptor for HCV, thereby
enabling overcoming many problems in the art.

15

Summary of the Invention

According to the present invention, there is provided a
protein having a molecular weight of about 24kD and capable
20 of specifically binding to a protein of hepatitis C virus,
or a functionally equivalent variant or fragment thereof.

It will be understood by the skilled person that molecular
weights measured as described below using electrophoresis
25 are inherently subject to interpretation since they are
measured relative to standard molecular weight markers.
However, in the context of this specification the expression
"24kd" is unambiguous when read in context, since only one
such protein is obtained by following the processes
30 described below with the defined characteristic of binding
to hepatitis C virus.

A significant characterising feature of the protein
according to the present invention is its ability to bind
35 specifically to an HCV protein, preferably an envelope
protein, particularly the E2 protein.

On the basis of this specificity and other features

T050707355260

described below, we infer that the 24kd protein of the invention is a cellular receptor for HCV.

We have shown that the protein is ubiquitous in humans amongst the cell types we have tested, paralleling the situation found for many other viruses of this type (such as vaccinia virus and influenza virus).

We have shown that the protein is species specific in a manner which matches the species specificity of HCV itself.

Our experiments have shown that the 24kd protein is functionally unglycosylated. Treatment with glycosidases does not affect the ability of the 24kd protein to bind to the E2 protein and does not appear significantly to reduce the molecular weight. We infer therefore that, if the protein is glycosylated at all, glycosylation must be restricted to a small number of sugar moieties and is not necessary for functional activity of the protein.

Our experiments have also shown that the protein is a transmembrane protein, again suggesting that it is a cellular receptor.

Finally, experiments with cell lines hyperexpressing the protein indicate that such cells are prone to aggregation suggesting that the protein may be an adhesion molecule of some form.

The 24kd protein may be in its naturally occurring form, albeit isolated from its native environment, or may be modified, provided that it retains the functional characteristic of at least binding to the E2 protein of HCV. For example, the 24 kd protein may be modified chemically to introduce one or more chemical modifications to the amino acid structure. It may include modifications of the amino acid sequence involving one or more insertions, deletions or replaced amino acids. It may, for example, be truncated by

the removal of a functional part of the transmembrane domain to facilitate ready production by recombinant DNA means in a suitable mammalian host cell (6).

- 5 The protein of the present invention may be purified from cells exhibiting binding to an HCV protein, such as the E2 protein.

According to the present invention there is provided a
10 process for the preparation of a protein according to the invention or a functionally equivalent variant or fragment thereof comprising the step of culturing cells exhibiting binding to an HCV protein and purifying from a cell preparation a protein according to the invention.

15 The cells may be transformed or untransformed mammalian cells and are suitably human cells.

The cells may be screened for binding to an HCV protein
20 using fluorescence flow cytometry or any other suitable assay. For example, the present description provides the information necessary to produce the 24kd protein or a functionally equivalent variant or fragment thereof which then itself be used to assay for further cells carrying the
25 protein.

The cell preparation may be a cell membrane preparation but is preferably a plasma cell membrane preparation.

30 Preferably the cells are selected and cloned to provide hyperexpression of the protein of the present invention.

We have discovered that the protein is precipitated by ammonium sulphate at between 33 and 50% of saturation.

35 Preferably, therefore, the cell preparation is subjected to an ammonium sulphate precipitation purification step employing ammonium sulphate at between 33 and 50%. Suitably

a first precipitation is conducted at less than 33% and precipitated material discarded followed by precipitation of the desired material at between 33 and 50%, most preferably 50%.

5

Preferably, the purification involves at least one step of hydrophobic interaction chromatography.

We have also discovered that the protein is stable to
10 acetone precipitation, thereby providing a still further characterisation and a useful purification process step.

Most preferably in optimised form, the process of purification comprises the steps of:

15

- i) preparing a plasma cell membrane preparation of mammalian cells selected for hyperexpression of the 24kd protein of the invention,
- 20 ii) subjecting the preparation to ammonium sulphate precipitation at less than 33% saturation and retaining the supernatant,
- iii) subjecting the supernatant to ammonium sulphate
25 precipitation at between 33 and 50% saturation and retaining the precipitate, and
- iv) resuspending the precipitate and subjecting it to hydrophobic interaction chromatography

30

As an alternative to purification from wild-type cell lines, the protein of the invention or a functionally equivalent variant or fragment thereof may be made by any suitable synthetic process including chemical synthesis. Suitably,
35 the protein or a functionally equivalent variant or fragment thereof is made by expression of a gene encoding the protein in a suitable host cell or animal.

According to a further aspect of the invention, there is provided a method for treating an infection of HCV comprising administering to a patient an amount of the protein of the invention or a functionally equivalent
5 variant or fragment thereof effective to reduce the infectivity of the virus.

Since the infection mechanism of HCV appears to depend, in part, upon the availability of a cell surface receptor,
10 making available a soluble form of the protein of the invention will act as an antagonist of binding of HCV to the cellular receptor thus reducing or preventing the infection process and thereby treating the disease.

15 A suitable soluble form of the protein of the invention might comprise, for example, a truncated form of the protein from which the transmembrane domain has been removed either by a protein cleavage step or, by design, in a chemical or recombinant DNA synthesis.

20 Alternatively, a hybrid particle comprising at least one particle-forming protein, such as hepatitis B surface antigen or a particle-forming fragment thereof, in combination with the protein of the invention or a
25 functionally equivalent variant or fragment thereof could be used as an antagonist of binding of HCV to the cellular receptor.

According to a further aspect of the invention, there is
30 provided a pharmaceutical composition comprising a protein of the invention or a functionally equivalent variant or fragment thereof, optionally as a pharmaceutically acceptable salt, in combination with a pharmaceutically acceptable carrier.

35 The pharmaceutical composition may be in any appropriate form for administration including oral and parenteral compositions.

A process is also provided for making the pharmaceutical composition, in which a protein of the present invention or a functionally equivalent variant or fragment thereof is brought into association with a pharmaceutically acceptable carrier.

According to a further aspect of the invention, there is provided a protein of the invention or a functionally equivalent variant or fragment thereof for use as a pharmaceutical.

According to a further aspect of the invention, there is provided the use of a protein of the invention or a functionally equivalent variant or fragment thereof in the manufacture of a medicament for the treatment of an HCV infection.

The ability of a protein of the invention or a functionally equivalent variant or fragment thereof to bind to HCV permits the use of the protein or a functionally equivalent variant or fragment thereof as a diagnostic for HCV infection, for example in an ELISA or RIA.

A soluble form of the protein could, for example, be used in an ELISA form of assay to measure neutralising antibodies in serum.

According to a further aspect of the invention, there is provided an assay for HCV antibodies in a serum sample comprising the step of allowing competitive binding between antibodies in the sample and a known amount of an HCV protein for binding to a protein of the invention or a functionally equivalent variant or fragment thereof and measuring the amount of the known HCV protein bound.

Preferably, the protein of the invention or functionally equivalent variant or fragment thereof is immobilised on a

solid support and the HCV protein, which may suitably be E2 HCV envelope protein, optionally recombinant E2 protein, is labelled, suitably enzyme labelled.

- 5 In an assay of this form, competitive binding between antibodies and the HCV protein for binding to the protein of the invention results in the bound HCV protein being a measure of antibodies in the serum sample, most particularly, neutralising antibodies in the serum sample.

10

- A significant advantage of the assay is that measurement is made of neutralising antibodies directly (i.e those which interfere with binding of HCV envelope protein to the cellular receptor). Such an assay, particularly in the form
15 of an ELISA test has considerable applications in the clinical environment and in routine blood screening.

- Also, since the assay measures neutralising antibody titre, the assay forms a ready measure of putative vaccine
20 efficacy, neutralising antibody titre being correlated with host protection.

- In a further aspect of the invention, there is provided a diagnostic kit comprising the protein of the invention or a
25 functionally equivalent variant or fragment thereof. Preferably the kit also contains at least one HCV labelled HCV protein, optionally enzyme labelled.

- The protein of the invention or a functionally equivalent
30 variant or fragment thereof may be used to screen for chemical compounds mimicking the HCV surface structure responsible for binding to the HCV receptor.

- According to a further aspect of the invention, there is
35 provided a method for screening chemical compounds for ability to bind to the region of HCV responsible for binding to a host cell, comprising measuring the binding of a chemical compound to be screened to a protein of the

invention or a functionally equivalent variant or fragment thereof.

This aspect of the invention encompasses the products of the screening process whether alone, in the form of a pharmaceutically acceptable salt, in combination with one or more other active compounds and/or in combination with one or more pharmaceutically acceptable carriers. Processes for making a pharmaceutical composition are also provided in which a chemical compound identified by the process of the invention is brought into association with a pharmaceutically acceptable carrier.

The chemical compound may be an organic chemical and may contain amino acids or amino acid analogues. Preferably however the chemical compound is a polypeptide or a polypeptide which has been chemically modified to alter its specific properties, such as the affinity of binding to the protein of the invention or a functionally equivalent variant or fragment thereof or its stability *in vivo*.

At present, the only available animal model is the chimpanzee, which is a protected species. Experiments on such animals pose a number of difficulties which together result in a very considerable expense (a one year experiment with one chimpanzee can cost \$70,000). Compared to this, a mouse model would be far more acceptable. Unfortunately, as described below the HCV receptor, whilst ubiquitous in humans and found in chimpanzees, is absent in other mammals. A transgenic mammal, for example a mouse, carrying the HCV receptor on the cell surface would be of great benefit to HCV research and the development of vaccines.

According to a further aspect of the invention, there is provided a transgenic non-human mammal, suitably a mouse, carrying a transgene encoding a protein of the invention or a functionally equivalent variant or fragment thereof.

The transgenic animal of the invention may carry one or more other transgenes to assist in maintaining an HCV infection.

There is also provided a process for producing a transgenic
5 animal comprising the step of introducing a DNA encoding a protein of the invention or a functionally equivalent variant or fragment thereof into the embryo of a non-human mammal, preferably a mouse.

10 Brief Description of the Drawings

Figure 1 is a schematic diagram describing an assay in which HCV receptor-binding ligands bind to receptors on HCV receptor target cells and are measured by first binding
15 rabbit anti-HCV antibody and then by binding a labelled anti-rabbit IgG-FITC F(ab') fragment prior to cell separation by FACScan analysis.

Figure 2 is a computer-generated histogram depicting the
20 results of a FACScan analysis of binding of HCV protein to haematopoietic cells (MOLT-4, Jurkat, K562, Daudi, EBV-B) and epithelial cells (Hela, Adenocarcinoma and Huh 7) resulting from binding with HCV proteins (filled curve unlabelled control, open curve labelled). The plot is of
25 cell population against fluorescence intensity.

Figure 3 is a computer-generated histogram depicting the results of a FACScan analysis of purified RA, purified RO, cord blood purif. RA, cord blood RA pha stim., KC3 T-cell
30 clone (TCC) and SAG S9 TCC, which were tested for binding to recombinant HCV E2 protein expressed in CHO cells (filled curve unlabelled control, open curve labelled). The plot is of cell population against fluorescence intensity.

35 Figure 4 is a set of computer-generated histograms depicting the results of a FACScan analysis of the binding of E2 CHO to MOLT-4 cells with and without treatment with beta mercaptoethanol (BSH) an S-S linkage reducing agent (filled

curve unlabelled control, open curve labelled). The plot is of cell population against fluorescence intensity.

Figure 5 is a set of computer-generated histograms depicting the results of a FACScan analysis of the binding of E2 CHO to MOLT-4 cells with and without treatment with Endo-H, a deglycosylating enzyme (filled curve unlabelled control, open curve labelled). The plot is of cell population against fluorescence intensity.

10

Figure 6 is a western-blot of membranes prepared from MOLT-4 cells and solubilized in different buffers (see page 22 for lane descriptions).

15 Figure 7 is a western blot of plasmatic membrane from MOLT-4 cells (see page 23 for lane descriptions).

Figure 8 is a western blot of MOLT-4 and PBMC membrane proteins (see page 23 for lane descriptions).

20

Figure 9 is a western blot of MOLT 4 cells membrane proteins treated with N-Glycosidase F (see page 26 for lane descriptions).

25 Figure 10 is a western Blot of MOLT-4 and COS-7 membranes electrophoresed in reducing and non reducing conditions (see page for 27 lane descriptions).

Figure 11 is a western blot of an experiment demonstrating immunoprecipitation of an E2-CHO/putative receptor complex (see page 29 for lane descriptions).

30

Figure 12 is a western blot of ammonium sulphate fractions from MOLT-4 cells membranes (see page 31 for lanes).

35

Figure 13 is a western blot of samples from a hydrophobic interaction chromatography experiment with an acetone precipitation step (see page 32 for lanes).

Detailed Description of the Invention

The arrangement of the detailed description is as follows:

5

	1.	General Description	13
	2.	Cellular Assay	13
	2.1.	FACS analysis of cells binding to E2	13
10	2.2.	Effect of E2 modification on binding	15
	2.2.1.	E2 reduction	16
	2.2.2.	E2 deglycosylation	16
	2.3.	Monoclonal antibody production	17
15	3.	Preparation of 24kd putative receptor	17
	3.1.	24kd protein preparation from MOLT-4 cells	17
	3.1.1.	Membrane purification	17
	3.1.2.	Plasma membrane purification	18
	3.2.	Hyperexpressing MOLT-4 cells	20
20	4.	Characterisation of Receptor	20
	4.1.	Western blot protocol	20
	4.1.1.	Membrane proteins	21
	4.1.2.	Plasma membrane proteins	22
25	4.1.3.	Western blot of PBMC cells	23
	4.2.	Cell surface expression of receptor	23
	4.3.	Effect of enzymes on 24kd protein binding	24
	4.3.1.	Flow cytometry	24
	4.3.2.	Western blot on MOLT-4/N-Glycosidase F	26
30	4.4.	Effect of reducing condition on binding	26
	5.	Optimising Purification	27
	5.1.	Immunoprecipitation	27
	5.2.	Ammonium Sulphate Fractionation	30
35	5.3.	Hydrophobic Interaction Chromatography	31
	5.4.	Acetone precipitation	32
	6.	Sequencing and cloning	33

T09070-1325260

6.1. Amino acid sequence	33
6.2. DNA sequence cloning and sequencing	33

1. General Description

5

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, cytofluorimetry and molecular biology, which are within the skill of the art. Such techniques are explained fully in
10 the literature (7).

The skilled person will understand and be familiar with the general methods and techniques of assay design and practice. The invention is described herein in sufficient detail for
15 the skilled person to understand and repeat the experiments disclosed.

Standard abbreviations for virus and proteins are used in this specification. All publications, patents and patent
20 applications cited herein are incorporated by reference. Envelope 1 (E1) and Envelope 2 (E2) of HCV refer to the proteins, and fragments thereof, the nucleotide sequence of which are published (EP-A-0318216 and EP-A-0388232 cited above). The nucleotides of the E1 and E2 genes and of the
25 encoded proteins vary in different HCV isolates. Therefore, the E1 and E2 for any HCV isolates are identified because included in the amino acid sequences 192-383 and 384-750 respectively.

30 E1 and E2 have been produced by recombinant DNA techniques using different expression systems (Spaete et al and Chien et al cited above).

2. Cellular Assay

35

2.1. FACS analysis of cells binding to E2

An experiment was performed with the aim of measuring the

ability of HCV protein to bind to various cell types which should have the putative HCV receptor.

Cells (10^5 /well) from the human T cell lymphoma, Molt-4
5 (commercially available and obtainable from the American Type Culture Collection), were pelleted in 96 U-bottom microplates (Costar) by centrifugation at 200 x g for 5 minutes at 4°C. Twenty microliters of HCV proteins (CHO expressed recombinant E2 protein) diluted in PBS in
10 different concentrations (from 10 µg/ml to 0.001 µg/ml) were mixed with the pellet of Molt-4 cells and incubated at 4°C for 60 minutes. Non bound HCV proteins were removed by two centrifugations in PBS at 200 x g for 5 minutes at 4°C.

15 Cells were subsequently incubated for 30 minutes at 4°C with various dilutions (from 1/10 to 1/300000) of sera from humans, chimps, rabbits or mice that were either infected with HCV or have been immunised with HCV recombinant proteins or the corresponding pre-immune sera as control.

20 The cells were washed twice in PBS and incubated for 30 minutes with the appropriate dilutions of fluorescein-isothiocyanate-conjugated antisera (either to human IgG, or rabbit IgG, or mouse IgG).

25 Cells were subsequently washed in PBS at 4°C, resuspended in 100 µl PBS and cell-bound fluorescence was analyzed with a FCScan flow cytometer (Becton & Dickinson). By using a dot plot display of forward and side scatter, the machine is
30 gated to include viable single cells and to exclude cell debris and clumps of cells. A total of 5000 events were collected and analyses of the data was done by using the Lysis II software program from Becton & Dickinson. This program produces histograms of each cell sample and
35 calculates the mean channel fluorescence of the cell population, which directly relates to the surface density of fluorescently labelled HCV proteins bound to the cells.

Mean fluorescence values (mean channel number) of cells incubated with or without HCV proteins and with immune or preimmune sera were compared. The threshold for positivity is set for each experiment by flow cytometric analysis of cells without HCV proteins bound which have been incubated with antisera to HCV proteins and the FITC labelled second antibody. A representative binding experiment is shown in Figure 1 which shows the separation achieved by flow cytometric analysis.

10

The experiment was also conducted with a variety of cell lines (for example haematopoietic cells other than MOLT-4 such as Jurkat, K562, Daudi, EBV-B (B-cell line transformed with Epstein-Barr virus and epithelial cells such as Hela, Adenocarcinoma and Huh 7) to identify cells capable of binding HCV proteins and therefore cells that have the putative receptor(s) for HCV following the protocol described above. It will be appreciated that repetition of this experiment is not necessary for the working of the present invention, but serves to prove the ubiquitous nature of the putative receptor (most of the cells are, in any event commonly available and were, in fact, obtained from the ATCC). The results were shown in Figure 2, together with those for MOLT-4 and demonstrate that the specific binding of E2 to cells is widespread, suggesting that the HCV receptor is ubiquitous.

In a similar series of experiments, purified RA, purified RO, cord blood purif. RA, cord blood RA pha stim., KC3 TCC and SAG S9 TCC, which were tested for binding to recombinant HCV E2 protein expressed in CHO cells (E2-CHO) and found to bind confirming that binding occurs to non-transformed cell lines. The results are shown in Figure 3.

35 2.2. Effect of E2 modification on binding

The effects of modifying the recombinant HCV protein E2, expressed in CHO cells (E2-CHO) on binding to MOLT-4 cells

were investigated using a reducing agent and a deglycosylating enzyme.

2.2.1. E2 reduction

5

25 μ l of E2-CHO SMC-PC (130 μ g/ml) in 20 mM potassium phosphate, 0.1 M NaCl, pH 6.0 were buffered at pH 8.0 with 1M Tris-base (total 1 μ l) and then added with BSH (beta mercaptoethanol) to a final concentration of 500mM; tubes
10 were flushed with nitrogen and the reaction allowed to proceed for 100 minutes at 37°C.

Samples from above were diluted 1:20 with RPMI medium and used for a FACS binding assay with MOLT-4 cells as described
15 above. The final concentration of BSH in the FACS assay was 12.5 mM and under these conditions, cells were verified to be alive in previous preliminary experiments (over 90% of cells still alive at 50 mM BSH).

20 The results in Figure 4 show that binding of MOLT-4 cells to recombinant E2 is substantially reduced on reduction with beta-mercaptoethanol, indicating a requirement for a correct E2 conformation maintained by S-S bridges.

25 2.2.2. E2 deglycosylation

25 μ l of E2-CHO SMC-PC (130 μ g/ml) in 20 mM potassium phosphate, 0.1 M NaCl, pH 6.0 were added with 30 μ l of 0.2 M NaH_2PO_4 to a final pH of 5.5 plus SDS to a final
30 concentration of 0.01%. Then 10 μ l of Endo-H stock was added to a final concentration of 200 mU/ml keeping the pH constant and the resulting sample was kept at 37°C for 20 hours. The sample was then diluted 1:20 with RPMI and used for in a FACS binding assay as described above.

35

The results in Figure 5 show that binding of MOLT-4 cells to recombinant E2 is substantially reduced on deglycosylation with Endo-H, indicating a requirement for glycosylation of

E2 for binding.

2.3. Monoclonal antibody production

5 Monoclonal antibodies were prepared using standard procedures and by immunising mice with recombinant HCV E2 produced in CHO cells (E2-CHO). Several cell lines were established which were capable of binding to E2-CHO as were cell lines capable of binding to E2 bound to MOLT-4 cells
10 and cell lines capable of neutralising the binding of E2-CHO to MOLT-4 cells.

3. Preparation of 24kd putative receptor

15 3.1. 24kd protein preparation from MOLT-4 cells

The 24kd protein was purified from MOLT-4 cells by membrane purification and by plasma membrane purification, the latter giving the better yield of protein.

20

3.1.1. Membrane purification

MOLT-4 cells were grown at 37°C, 5% CO₂ in RPMI buffered with 25 mM Hepes in a growth medium containing Fetal Calf
25 Serum (FCS - final concentration 5%), 1 mM glutamine, 100 µg/ml kanamycin, MEM vitamins (Gibco), 1mM sodium pyruvate, MEM non essential amino acids (Gibco), 5 x 10⁻⁵M β-mercaptoethanol.

30 Cells were harvested after reaching a density of 750,000 - 1,000,000 cells per ml.

The growth medium containing cells was centrifuged at 300g for 10 minutes to pellet down the cells. Pelleted cells
35 were washed three times in PBS Buffer (resuspended and recentrifuged).

The cell pellet was resuspended in hypotonic solution at 1

09561-010504
F05070-1925260

ml of hypotonic solution per 100×10^6 cells.

The hypotonic solution contained Tris (10 mM), NaCl (10 mM),
CaCl₂ (0.2 mM), MgCl₂ (1.5 mM), PMSF (1.0 mM), aprotinin
5 (2.0 µg/ml), pepstatin (0.7 µg/ml) and leupeptin (0.5
µg/ml).

Cells were left at 4°C under gentle shaking for 20 minutes
and then disrupted with 25 strokes of a Potter manual
10 homogenizer.

Membranes were recovered after sequential centrifugation of
the supernatant at 100g for 7 minutes, 3500 g for 10 minutes
and 40,000 g for 60 minutes. The pellet obtained from the
15 above was dissolved in suitable buffer.

The buffer used for dissolution of the 40,000 g membrane
pellet contained 1% Triton X-100 in PBS buffer pH 7.4, 8 mM
Chaps in PBS buffer pH 7.4 and 4 M Urea in sodium phosphate
20 buffer pH 7.4.

All the buffers used for membrane solubilisation contained
protease inhibitors at the concentrations reported above for
the hypotonic solution and were used at a ratio of 200 µl of
25 buffer per 5×10^8 cells.

Solubilised material was centrifuged at 100,000 g for 60
minutes and the supernatant kept for further use after
estimation of protein content by BCA method.

30

The material obtained was subjected to analyses as described
below.

3.1.2. Plasma membrane purification

35

The procedure for plasma membrane purification was based on
Morre' D.J. et al. (8).

MOLT-4 cells were grown at 37°C, 5% CO₂ in RPMI buffered with 25 mM Hepes in a growth medium containing Fetal Calf Serum (FCS - final concentration 5%), 1 mM glutamine, 100 µl/ml kanamycin, MEM vitamins (Gibco), 1mM sodium pyruvate, 5 MEM non essential amino acids (Gibco), 5 x 10⁻⁵ M β-mercaptoethanol.

Cells were pelleted from culture medium and washed three times with PBS.

10

The pelleted cells were resuspended in 0.2 mM EDTA, 1 mM NaHCO₃ containing the following protease inhibitors: PMSF (1.0 mM), aprotinin (2.0 µg/ml), pepstatin (0.7 µg/ml), leupeptin (0.5 µg/ml) at a ratio between buffer and cells of 2 ml per each 10⁸ cells.

Resuspended cells were disrupted with a Polytron homogenizer using an S25 N10 G probe for 40 seconds at 9500 rpm. Cell disruption was verified by optical microscope. The homogenate was centrifuged at 300 g and the resulting supernatant further centrifuged at 23,500 g for 60 minutes. The resulting pellet was resuspended in 0.2 M potassium phosphate pH 7.2 containing protease inhibitors in the ratios described above. The buffer volume was 1 ml each 5 x 10⁸ cells.

The membrane suspension was partitioned across the following two phase system:

20% (w/w) T500 Dextran	13.2g
40% (w/w) PEG 3350	6.6 g
0.2 KP, pH 7.2	0.8 ml
membrane susp.	5.0 g
Distilled water	up to 35 g

35

The sample as chilled at 4°C and the tubes were inverted 30 to 40 times keeping the temperature constant. The sample was then centrifuged on a swinging bucket rotor at 150-200 g for

5 minutes at 4°C. The upper phase was removed and five-fold diluted with 1mM sodium bicarbonate containing protease inhibitors. The membranes were collected by centrifugation at 30,000 g for 30 minutes.

5

The pellet was dissolved in a suitable buffer and centrifuged at 100,000 g for 60 minutes to eliminate undissolved material.

- 10 The material obtained was subjected to analyses as described below.

3.2. Hyperexpressing MOLT-4 cells

- 15 A further cell line capable of hyperexpression of the characteristic binding ability for E2 was prepared by selecting and recloning MOLT-4 cells binding E2 strongly. The resulting cell-line showed a markedly greater binding affinity for E2 than the wild-type strain.

20

4. Characterisation of Receptor

4.1. Western blot protocol

- 25 The following experiments demonstrate binding of E2 to purified 24kd protein in a western blot of proteins from MOLT-4 cells purified from membranes and from plasma membranes and from peripheral blood mononuclear cells (PBMC).

30

Unless otherwise indicated, all SDS-PAGE experiments were performed according to Laemmli et al (9), samples of solubilised membranes were run under non-reducing conditions and without boiling before each electrophoretic run.

35

After electrophoretic transfer (Western blot) in buffer containing 25 mM Tris, 192 mM glycine, 20% methanol at constant electric field of 10 Volts/cm, blotted transfer

supports were saturated for 2 hours in PBS buffer pH 7.4 containing 0.05% Tween 20 and 10% powdered skimmed milk at room temperature. After 1 x 15 minutes and 2 x 5 minutes, washes in PBS, 0.05% Tween 20 containing 1% powdered skimmed milk, transfer supports were incubated overnight with E2-CHO recombinant protein at a concentration of 1-2 $\mu\text{g/ml}$ dissolved in PBS buffer containing 0.05% Tween 20, 1% milk, 0.02% sodium azide. Negative control transfer supports (blotted with the same samples) were incubated for the same time in the same buffer without E2-CHO protein.

To detect E2-CHO recombinant protein bound to the transfer supports, these were incubated with the culture supernatant of an hybridoma named 291A2 (a monoclonal antibody that recognises epitopes exposed on E2 when bound to its putative receptor) at 1:500 dilution in PBS, Tween 0.05%, milk 1% for 2 hours.

After this step, transfer supports were washed 1 x 15 minutes and 2 x 5 minutes with PBS Tween 0.05% milk 1% solution. Transfer supports were then incubated for 1 hour with biotin conjugated goat anti-mouse immunoglobulin specific polyclonal antibody of commercial source (PharMingen, San Diego, CA, USA) at 1:2000 dilution in the PBS/Tween/Milk solution mentioned above. After this step, transfer supports were washed 1 x 15 minutes and 2 x 5 minutes with PBS/Tween/Milk. Finally transfer supports were incubated for 1 hour with Extravidin®-Peroxidase (Sigma Immunochemicals Co., St Louis, MO, USA) at 1:2500 dilution in PBS/Tween/Milk. Transfer supports were then washed 1 x 15 minutes and 4 x 5 minutes with PBS buffer pH 7.4 containing 0.05% Tween 20. Chemiluminescent staining was performed using ECL[™] western blotting detection reagents (Amersham, UK).

35

4.1.1. Membrane proteins

A membrane preparation was prepared as described above.

Membrane pellets resulting from 40,000 g centrifugation were dissolved in buffers reported below and centrifuged at 100,000 g to remove undissolved material. Pellets were
5 reextracted with 1% Triton X-100 in PBS pH 7.4.

Following SDS-PAGE (15µg/lane) and blotting, the transfer supports were incubated with E2-CHO recombinant protein as described above.

10

The results are shown in Figure 6.

<u>Lane</u>	<u>Description</u>
1A	4M Urea in 50 mM sodium phosphate pH 7.2
15 2A	Pellet from lane 1A sample solubilized in 1% Triton X-100 in PBS pH 7.4
3A	1% Triton X-100 in PBS pH 7.4
4A	Pellet from lane 3A sample solubilized in 1% Triton X-100 in PBS pH 7.4
20 5A	0.01% Triton X-100 in PBS pH 7.4
6A	Pellet from lane 5A sample solubilized in 1% Triton X-100 in PBS pH 7.4

1B to 6B are negative controls for the corresponding samples
25 in lanes 1A to 6A.

The protein band at 24kd is clearly visible.

4.1.2. Plasma membrane proteins

30

A plasma membrane preparation was prepared as described above.

Plasma membranes were solubilized in PBS pH 7.4 containing
35 1% Triton X-100 and subjected to Laemmli SDS-PAGE. The transfer support was incubated with E2-CHO recombinant protein.

The results are shown in Figure 7.

<u>Lane</u>	<u>Description</u>
1A	plasma membranes, 10 µg total protein content
5 2A	plasma membranes, 5 µg total protein content

Lanes 1B and 2B are negative controls for the corresponding samples in lanes 1A and 2A.

10 The protein band at 24kd is clearly visible.

4.1.3. Western blot of PBMC cells

To assess whether the 24kd protein could be identified in normal cells a sample of peripheral blood mononuclear cells was purified using the procedure described above and subjected to western blotting as described above.

The results are described in Figure 8.

20

<u>Lane</u>	<u>Description</u>
1/2	Molt-4 membrane proteins
3	PBMC membrane proteins (22µg/ml)
4	PBMC membrane proteins (44µg/ml)

25

The negative control lanes are marked "-E2 CHO"

4.2. Cell surface expression of receptor

30 Employing the protocols described above, various cell types were analysed using FACscan and western blotting for the presence of the 24kd protein putative HCV receptor.

			<u>FACS</u>	<u>W B</u>	<u>HV</u>
5	T and B lympho	human	+++	+++	++
	Monocytes	human	+++		++
	HeLa	human	++		++
	Gastric carcinoma	human	++		++
	Hepatoma cells	human	+++	+++	++
10	Myoblastoma	human	+		-
	Fresh liver cells	Green monkeys	-	-	-
	Lymphomonocytes	rabbit	-		-
	Fresh liver cells	rabbit		-	-
	Any cells	mouse	-		-

30 The proteinaceous nature of the receptor was demonstrated when cells pretreated with proteases abolished binding capability of E2 CHO whereas phospholipase treatment of cells did not affect the binding, suggesting that the cellular attachment proteins were not
35 glycosylphosphatidylinositol anchor linked. The E2 binding site on Molt 4 cells was sensitive to all protease used, which included both serine proteases, such as trypsin, and a thiol protease, such as papain.

The results of proteolytic treatment demonstrated the involvement of membrane proteins in envelope protein binding and were as follows:

5	Treatment	Concentration	Fluorescence intensity
			(% of control)
10	Control		100
	Pronase E	10 µg/ml	36
	Pronase E	100 µg/ml	34
15	Trypsin	100 µg/ml	33
	Papain	100 µg/ml	42
	Phospholipase C	3U/ml	100
20	(from <i>Bacillus cereus</i>)		
	Phospholipase C	25U/ml	96
25	Neuraminidase	50mU/ml	100

Cells (10^6 ml^{-1}) were incubated for 60 min at 37°C in RPMI 1640/Hepes medium plus the enzymes indicated above. The cells were centrifuged, resuspended in fresh medium and incubated with E2 CHO protein (3µg/ml). Purified anti E2 CHO monoclonal antibody (1.5 µg/ml) was used as a second step. Purified phycoerythrin-labelled rabbit anti mouse antibody (5 µg/ml) was used as a third step reagent. A total of 5000 cells per sample was evaluated with a FACScan flow cytometer.

Enzymes were used at a concentration that did not affect cell viability as measured by propidium iodine exclusion

during FACS analysis.

Fluorescence was recorded as arbitrary units (channel numbers) on a logarithmic scale and median intensities
5 determined. Data from individual experiments were normalized with respect to the fluorescence of unstained control samples and value are expressed as percentages of the fluorescence intensities in the stained control samples.

10 4.3.2. Western blot on MOLT-4/N-Glycosidase F

Peptide N-Glycosidase F treatment was performed incubating membrane proteins (50 μ g) overnight at 37°C in phosphate buffer pH 7.4, 25 mM EDTA plus enzyme (50 U/ml) and
15 successively loaded on 12% SDS PAGE.

To show the activity N-Glycosidase F enzyme (PNGase F), as control, gp 120 polypeptide was used in the same experiment (data not shown).

20

The results are shown in Figure 9.

<u>Lane</u>	<u>Description</u>
1	+/-ve control
25 2	treated and boiled membrane
3	untreated and boiled membrane
4	treated membrane
5	untreated membrane

30 These results show that treatment of a MOLT 4 membrane preparation with Peptide-N-glycosidase F, which hydrolyzes all N-linked glycans, does not abolish E2 CHO binding.

4.4. Effect of reducing condition on binding

35

A western blot of MOLT-4 and COS-7 membranes, prepared as described above, were electrophoresed in reducing and non reducing conditions to establish the requirement or

097551-0330
FOUO-155260

otherwise for disulphide bridges in the 24kd protein, by measuring the binding of E2-CHO to the transfer support.

Transfer supports were incubated with E2-CHO recombinant protein as described above.

The results are shown in Figure 10.

	<u>Lane</u>	<u>Description</u>
10	1A	COS-7 membranes in non reducing SDS Laemmli buffer
	2A	MOLT-4 membranes in non reducing SDS Laemmli buffer
	3A	COS-7 membranes in SDS Laemmli buffer containing 5% β -SH
15	4A	MOLT-4 membranes in SDS Laemmli buffer containing 5% β -SH

1B to 4B are negative controls for the corresponding lanes 1A to 4A.

5. Optimising Purification

5.1. Immunoprecipitation

Membrane Proteins Solubilization

A membrane preparation from 400 million MOLT-4 cells (A2A6 subclone) was treated with 200 μ l of PBS buffer, pH 7.4, containing CHAPS 7.5 mM and the following protease inhibitors in μ l/ml: PMSF 35, aprotinin 2, pepstatin 0.7, leupeptin 0.5. After treatment with the above buffer, the resulting suspension was centrifuged at 100,000 g for 1 hour and the clear supernatant underwent immunoprecipitation experiments. The final protein concentration based on BCA protein assay (Pierce, USA) was 2.7 mg/ml.

Incubation with E2 recombinant envelope protein

200 μ l of membrane protein solution (2.7 mg/ml) in PBS-CHAPS were added to 15 μ l of CHO-produced E2 (Batch P4) solution.

- 5 The stock concentration of E2-P4 protein was 130 μ l/ml and its final concentration in the protein membrane solution was 9.75 μ g/ml.

The mixture was kept overnight under stirring at 4°C.

10

Incubation with Rabbit anti-E2 antisera

The resulting solution was divided into two aliquots of 100 μ l and each was mixed with 5 μ l of preimmune and
15 postimmune antiserum from a rabbit (R#1) previously immunized with E2 protein. The final dilution of antisera was 1:20. Incubation was performed for 1 hour at 4°C.

Addition of Protein-A Sepharose CL-4B

20

Protein-A Sepharose CL-4B resin (Pharmacia, Sweden) was extensively washed with PBS containing 7.5 mM CHAPS at pH 7.4, and 30 μ l of compact slurry (capacity of matrix is 20 mg of human Ig per ml of slurry) were added to each 100 μ l
25 sample resulting from the step above. Incubation was performed under stirring for 1 hour at 4°C.

The samples were centrifuged to pellet down the resin and the supernatant was removed, mixed with Laemmli-Buffer
30 (without reducing agent) and kept for SDS-PAGE. The resin pellet was washed twice with 500 μ l of PBS-CHAPS (10 min each wash at 4°C) and then the pellet was treated with 50 μ l of Laemmli Buffer containing 5M urea. The resulting supernatant was subjected to SDS-PAGE.

35

SDS-PAGE and Immunoblot

The samples from the steps above, that is, supernatant

09551-0050
T05010-1535460

containing material not absorbed on Protein-A matrix (SN) and material desorbed from Protein-A matrix (ProtA) from both preimmune and postimmune antisera, were loaded on SDS-PAGE gel in non reducing buffer and without heating. After the run, the gels were electroblotted on nitrocellulose paper in 20% methanol Tris-Glycine buffer and were subjected to immunostaining as described above. Incubation with E2 protein was performed overnight using E2 SMC-PC at 1.73 $\mu\text{g/ml}$ in PBS 0.05% Tween 20.1% milk.

10

The samples loaded on SDS-PAGE were:

- A) Supernatant (material not retained by Prot-A) from Preimmune antiserum,
- 15 B) Prot-A desorbed material from PREimmune antiserum,
- C) Supernatant from POSTimmune antiserum, and
- D) Prot-A desorbed material from POSTimmune antiserum

Three sets of these samples were loaded on gel, one was stained directly on gel the other two underwent immunostain, one incubated with E2 the other as negative control.

The nitrocellulose transferred support was incubated with E2-CHO SMC-PC recombinant protein at 1.73 $\mu\text{g/ml}$ followed by 25 291A2 hybridoma culture supernatant (containing a monoclonal antibody that recognises epitopes exposed on E2 when bound to its putative receptor), biotinylated polyclonal anti-mouse Ig antibodies and peroxidase labelled Extravidin[™] (Sigma Immunochemicals, USA). Chemiluminescent staining 30 obtained with ECL-Luminol (Amersham, GB), exposure 1 minute.

The results are shown in Figure 11.

<u>Lane</u>	<u>Description</u>
35 1A	molecular weight standard
2A	empty
3A	sample incubated with preimmune rabbit serum - supernatant

- 4A sample incubated with preimmune rabbit
serum - Protein-A bound
- 5A sample incubated with postimmune rabbit
serum - supernatant
- 5 6A sample incubated with postimmune rabbit
serum - Protein-A bound

The negative controls employed the nitrocellulose membrane incubated with 291A2 hybridoma culture supernatant followed
10 by biotinylated polyclonal anti-mouse Ig antibodies and peroxidase labelled streptavidin. 1B to 4B correspond to 3A to 6A respectively.

5.2. Ammonium Sulphate Fractionation

15

Membranes were prepared as reported in the membrane preparation protocol from MOLT-4 cells and solubilized in PBS buffer pH 7.4 containing 8 mM CHAPS. The protein concentration estimated on the basis of BCA assay ranges
20 from 1.8 and 2.5 mg/ml.

Solubilized membranes were mixed with an ammonium sulphate (AS) saturated solution in a volume sufficient to obtain 25% saturation of ammonium sulphate (i.e. the final
25 concentration of AS is 25% of the starting saturated solution). The sample was allowed to stand in melting ice for 2 hours and then centrifuged at 15800 g for 30 minutes.

The supernatant was mixed with AS saturated solution to a
30 final saturation of 50%. The sample was allowed to stand for 2 hours on melting ice and then filtered on a Spin-X[®] centrifuge filter unit (Costar, Cambridge, MA, USA) for 15 minutes at 4°C.

35 The precipitates obtained above were dissolved in suitable buffers and undergo further treatment.

The pellets were redissolved in PBS pH 7.4 containing 10M

urea and underwent Laemmli SDS-PAGE. The volumes of AS fractions were loaded in such a way that the amount of putative receptor should be comparable in different samples.

- 5 The transfer support was incubated with E2-CHO recombinant protein as described above.

The results are shown in Figure 12 and show that precipitation of p24 occurs in the range of 33 to 50% of
10 saturation.

<u>Lane</u>	<u>Description</u>
1A	Starting membranes
2A	20% AS fraction
15 3A	33% AS fraction
4A	43% AS fraction
5A	50% AS fraction
6A	60% AS fraction

20

5.3. Hydrophobic Interaction Chromatography

1.5 ml of solubilized membranes from MOLT-4 cells (protein concentration 2.5 mg/ml) were pre-fractionated at 25% of
25 saturation of ammonium sulphate and the supernatant from this step was brought to 50% saturation of AS. The precipitate obtained was resuspended in 200 μ l of PBS containing ammonium sulphate at 25% of saturation. The undissolved material was pelleted by centrifugation at 15800
30 g for 30 minutes. The supernatant obtained was incubated with 200 μ l of Phenyl-Sepharose matrix (Pharmacia, Uppsala, Sweden), previously equilibrated in PBS pH 7.2 containing AS at 25% of saturation, for 2 hours at room temperature.

- 35 The non retained material was recovered by filtering on a Spin-X[™] centrifuge filter units (Costar, USA).

The matrix of Phenyl-Sepharose was washed twice with 100 μ l

of PBS, 25% AS saturation and once with 300ml of the same buffer. The matrix was then eluted with PBS pH 7.4 (200 μ l) and then with PBS, pH 7.4 containing 20 MeOH. Finally, the matrix was treated with 40 μ l of non reducing Laemmli
5 buffer.

Samples containing ammonium sulphate (i.e. non retained and wash material) were dialysed against 8M urea in PBS, pH 7.4.

10 All samples underwent SDS-PAGE analysis and Western Blot.

5.4. Acetone precipitation

50 μ l of membranes from MOLT-4 cells solubilized in 8 mM
15 CHAPS in PBS, pH 7.4 were mixed with 200 μ l of acetone.

The sample was centrifuged at 15800g for 15 minutes and the supernatant was discarded. The obtained precipitate was dissolved in non reducing Laemmli sample buffer and
20 underwent SDS-PAGE and Western Blot. The transfer supports incubated with E2-CHO recombinant protein as described above.

The results of the combined HIC and acetone precipitation
25 experiment are shown in Figure 13.

<u>Lane</u>	<u>Description</u>
1A	Starting membranes (16 μ l total protein content)
30 2A	material non retained on matrix
3A	wash
4A	material eluted with PBS, pH 7.4
5A	material eluted with PBS, pH 7.4 containing 20% Methanol
35 6A	material eluted with Laemmli Buffer
7A	membranes solubilized in Triton 1% PBS, pH 7.4 (26 μ g total protein)
8A	acetone precipitate from sample 7A

Samples from 1B to 8B correspond to samples from 1A to 8A

These experiments show that ammonium sulphate precipitated
5 material can be redissolved in suitable conditions and
undergo hydrophobic interaction chromatography. The 24kd
HCV putative receptor protein binds to Phenyl Sepharose and
can be recovered from this matrix.

10 The membrane extract can be precipitated with acetone
without loss of binding capacity of HCV putative receptor.

6. Sequencing and cloning

15 6.1. Amino acid sequence

The amino acid sequence of the 24kd protein may be
elucidated either by inference from the cloned DNA or by
microsequencing of protein prepared by one of the processes
20 described above. Based upon the molecular weight of the
protein (and the knowledge that, if glycosylated it is only
glycosylated to a small extent) it is expected that the
protein will have approximately 210 - 230 amino acids
(allowing the average of 110 daltons per amino acid).

25

6.2. DNA sequence cloning and sequencing

The DNA sequence of the 24kd protein may be determined by
one of a number of techniques known to the art, such as
30 λ gt11 "shotgun" cloning where a DNA library is produced,
suitably from a hyperexpressing cell-line (see above) and
fragments of DNA were caused to express in prokaryotic or
eukaryotic cell, the products being screened using
antibodies to the 24kd protein or by binding to recombinant
35 E2-CHO.

Once identified, the DNA encoding the 24kd protein may be
used to produce large quantities of the protein which, as a

result of its binding to HCV may prove useful in an assay for HCV infection or for the manufacture of a medicament for treating HCV infection.

- 5 Alternatively, the DNA may be used to prepare transgenic animals bearing the 24kd protein which may then serve as animal models for HCV infection.

10 It will be understood that the invention is described above by way of example and modifications within the scope and spirit of the invention may be made without the need for undue experiment or the exercise of inventive ingenuity.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197

References

1. European patent application EP-A-0318216
2. European patent application EP-A-0388232
- 5 3. Choo et al PNAS USA (1991) 88 2451-2455
4. Chien, D.Y. et al PNAS USA (1992) 89 10011-10015
5. Spaete, R.R. et al Virology (1992) 188 819-830
6. Gething et al Nature [needs complete reference]
- 10 7. "Flow Cytometry" in Methods of Cell Biology, 1990 Vol. 33 Academic Press San Diego
8. Morre' D.J. et al., Methods Enzymol. (1994) 228, 448-450
9. Laemmli et al Nature (1970) 27 680